Pipex expects November NDA filing for Coprexa
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Ann Arbor-based Pipex Pharmaceuticals anticipates filing its lead compound, Coprexa (oral tetrathiomolybdate), in November for the treatment of initially-presenting neurologic Wilson's disease, the firm announces Sept. 21 after completing pre-NDA meetings with FDA. Pipex is also developing oral tetrathiomolybdate - an oral small-molecule, anti-copper agent - for fibrotic disorders...